KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Operating Margin (2016 - 2025)

Historic Operating Margin for TherapeuticsMD (TXMD) over the last 15 years, with Q3 2025 value amounting to 109.95%.

  • TherapeuticsMD's Operating Margin rose 973600.0% to 109.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 61.8%, marking a year-over-year increase of 3564900.0%. This contributed to the annual value of 270.3% for FY2024, which is 3843100.0% up from last year.
  • Per TherapeuticsMD's latest filing, its Operating Margin stood at 109.95% for Q3 2025, which was up 973600.0% from 73.0% recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Operating Margin ranged from a high of 104.95% in Q4 2024 and a low of 4269.25% during Q2 2022
  • In the last 5 years, TherapeuticsMD's Operating Margin had a median value of 221.63% in 2025 and averaged 971.35%.
  • In the last 5 years, TherapeuticsMD's Operating Margin plummeted by -41163100bps in 2022 and then surged by 37035800bps in 2023.
  • Over the past 5 years, TherapeuticsMD's Operating Margin (Quarter) stood at 189.48% in 2021, then skyrocketed by 137bps to 70.65% in 2022, then tumbled by -554bps to 320.92% in 2023, then surged by 133bps to 104.95% in 2024, then plummeted by -205bps to 109.95% in 2025.
  • Its Operating Margin stands at 109.95% for Q3 2025, versus 73.0% for Q2 2025 and 221.63% for Q1 2025.